Abstract:Abstract Background: Many studies have indicated that histone deacetylases (HDAC) activity is always increased in a lot of human tumors, and inhibition of HDAC activity are promising new strategies in the treatment of cancers. Chidamide (CS055/HBI-8000), a novel histone deacetylases inhibitor (HDACi) of the benzamide class, is currently under clinical trials. Despite emerging information on the effect of chidamide in multiple cancers, little is yet known about mechanism of action, and there were few reports about this drug's effects on myelodysplastic syndromes (MDS). In this study, we aimed to investigate the antitumor activities of chidamide on MDS cell line SKM-1 and to explore the possible mechanism. Methods: We treated MDS cells with different concentrations of chidamide. The effect of chidamide on HDAC activity of MDS cells was studied by using a HDAC Fluorometric Activity Assay Kit. The induction of histone acetylation was confirmed by detecting acetylated histone H3 and H4 using Western blot analysis. The effect of chidamide on the proliferation of MDS cells was analyzed by Cell Counting Kit (CCK-8) assay. Apoptosis were detected by Annexin V/propidium iodide (PI) double-labeled cytometry. Cell cycle was analyzed by a PI method. The acetylation levels of genes promoterassociated histone H3 and H4 were examined by chromatin immunoprecipitation (ChIP) and quantitative real-time PCR. Quantitativereal-time PCR and Western blot were used to detect the expression of signaling pathway factors (SOCS3, JAK2, STAT3,Bcl-XL,Bcl-2 and Mcl-1). Results: Our results demonstrated chidamide suppressed MDS cells growth in a time- and dose-dependent manner, and induced cell apoptosis and cell cycle arrest at G0/G1phase. Chidamide was able to significantly inhibit the HDAC activity and increase the acetylated histoneH3 and H4 of MDS cells. ChIP analysis further indicated that chidamide induced acetylated histones accumulation in the promoter of SOCS3.Moreover, chidamide upregulated the mRNA and protein expression ofSOCS3, and also significantly downregulated JAK2/STAT3 signaling. Further, we identified reduced expression of STAT3 downstream targets with treatment of chidamide, including Bcl-XL, Bcl-2 and Mcl-1, which may explain the cytotoxic effects of chidamide on MDS cells. Conclusion: These results demonstrate that chidamide possesses significant cytotoxic effects on MDS cells mainly through histone modifications of SOCS3 and consequently JAK2/STAT3 signaling inhibition. Therefore, Our data provide rationale for clinical investigation of chidamide in MDS. Disclosures No relevant conflicts of interest to declare.

Discovery of an orally active subtype-selective HDAC inhibitor, chidamide, as an epigenetic modulator for cancer treatment

Preclinical and clinical studies of chidamide (CS055/HBI-8000), an orally available subtype-selective HDAC inhibitor for cancer therapy.

Chidamide in Relapsed or Refractory Peripheral T Cell Lymphoma: A Multicenter Real-World Study in China

Chidamide (CS055/HBI-8000): a new histone deacetylase inhibitor of the benzamide class with antitumor activity and the ability to enhance immune cell-mediated tumor cell cytotoxicity

Chidamide, A Novel Histone Deacetylase Inhibitor, Displays Potent Antitumor Activity Against Mds Cells Mainly Through Jak2/Stat3 Signaling Inhibition

Chidamide, a Novel Histone Deacetylase Inhibitor, Synergistically Enhances Gemcitabine Cytotoxicity in Pancreatic Cancer Cells

Phase Ii Study of Chidamide (cs055), A New Subtype-Selective Oral Histone Deacetylase Inhibitor, in Patients with Relapsed or Refractory Peripheral T-Cell Lymphoma

Therapeutic Effects Of The Novel Subtype-Selective Histone Deacetylase Inhibitor Chidamide On Myeloma-Associated Bone Disease

Chidamide, a Novel Histone Deacetylase Inhibitor, Inhibits the Viability of MDS and AML Cells by Suppressing JAK2/STAT3 Signaling.

Phase Ii Study Of Chidamide, A New Subtype-Selective Oral Histone Deacetylase Inhibitor, In Patients With Relapsed Or Refractory Cutaneous T-Cell Lymphoma

A New Strategy to Target Acute Myeloid Leukemia Stem and Progenitor Cells Using Chidamide, a Histone Deacetylase Inhibitor.

Therapeutic potential of tucidinostat, a subtype-selective HDAC inhibitor, in cancer treatment

Phase I Study of Chidamide (CS055/HBI-8000), a New Histone Deacetylase Inhibitor, in Patients with Advanced Solid Tumors and Lymphomas

Discovery of Epigenetic Modulators Targeting Hdacs and Ezh2 Simultaneously for the Treatment of Hematological Malignancies

A Novel Histone Deacetylase Inhibitor Chidamide Induces G0/G1 Arrest and Apoptosis in Myelodysplastic Syndromes

Results from a Multicenter, Open-Label, Pivotal Phase II Study of Chidamide in Relapsed or Refractory Peripheral T-cell Lymphoma.

Chidamide, A Novel Histone Deacetylase Inhibitor, Inhibits Laryngeal Cancer Progression in vitro and in vivo

A Novel Histone Deacetylase Inhibitor Chidamide Induces Apoptosis of Human Colon Cancer Cells

Preclinical Evaluation of the HDAC Inhibitor Chidamide in Transformed Follicular Lymphoma.

Chidamide, a subtype-selective histone deacetylase inhibitor, enhances Bortezomib effects in multiple myeloma therapy

The Novel Subtype-Selective Histone Deacetylase (Hdac) Inhibitor, Chidamide, Exerts Dual Anti-Myeloma And Bone Protective Effect In Vitro And In Vivo